What Nu Skin Enterprises (NUS) Said on Its Q3 Earnings Call
Nu Skin (NUS) reported Q3 cash of $164.9M, debt of $203.7M, and no share repurchases. It placed 41,000 Prysm iO devices and saw a 10% scan-to-purchase conversion rate. LifePak sales grew 3% YTD. The company plans an India launch in 2027 and a regional manufacturing structure. Q4 revenue is forecast at $310M-$340M, with adjusted EPS of $0.11-$0.21.
How this was made
The 30-second read
Why it matters
The earnings call revealed lower-than-expected earnings guidance and a projected loss per share, which may trigger short‑term price weakness.
Market read
Guidance release provides fresh data for traders to adjust positions in NUS and assess sector sentiment.
What to watch
Potential upside from AI‑enhanced device conversion rates and upcoming product rollouts in 2027.
Background
Nu Skin Enterprises (NYSE:NUS) is a global direct‑selling company focused on personal care and wellness products.
Ticker impact
Nu Skin disclosed Q4 revenue guidance of $310M-$340M and adjusted EPS of $0.11-$0.21, plus full-year outlook, marking the first public release of these numbers.
likely downside as investors price in lower earnings outlook
The company lowered its full-year adjusted EPS range and reported a loss per share, which typically triggers sell pressure.
Market effects
Direct‑selling wellness sector may see broader scrutiny as peers evaluate similar guidance.
Limited to U.S. and international markets where Nu Skin operates.
Modest; the company is a small‑cap player with niche exposure.
Counterpoint
If the market overreacts to the guidance, a bounce could occur on the back of strong cash position and upcoming India launch.
Key entities
- companyNu Skin Enterprises
Publicly listed direct‑selling wellness company.
